TKT gives up on Replagal
Executive Summary
Transkaryotic Therapies withdraws BLA for Replagal in Fabry disease after FDA indicates that a comparison trial against Genzyme's Fabrazyme would be a prerequisite for approval. TKT submitted a special protocol assessment to the agency in November to open a discussion about a potential regulatory pathway (1"The Pink Sheet" Nov. 10, 2003, p. 17). Replagal and Fabrazyme were on near-identical development tracks for orphan drug approval; FDA cleared Genzyme's product in April (2"The Pink Sheet" April 28, 2003, p. 3)...
You may also be interested in...
TKT Replagal Approval Path Will Begin With Request For Protocol Assessment
Transkaryotic Therapies hopes to begin discussion on a potential approval pathway for the Fabry disease agent Replagal in November via a request for an FDA special protocol assessment, CEO Michael Astrue said during an Oct. 29 conference call
Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed
FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.